{"brief_title": "Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy", "brief_summary": "EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor. This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with placebo in subjects with neuropathic pain associated with diabetic neuropathy.", "condition": ["Diabetes Mellitus", "Diabetic Neuropathy, Painful"], "intervention_type": ["Drug"], "intervention_name": ["EAA-090"], "criteria": "Inclusion Criteria: - Women of childbearing potential must have a negative serum pregnancy test result at screening - Diabetes mellitus (type I or II) that is controlled by oral or parenteral hypoglycemic agents or diet - Diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy Exclusion Criteria: - Pregnancy, lactation, or plans to become pregnant during the study - Depo-Provera or oral contraceptives that have been taken for less than 1 month before study day 1 if not using another medically accepted form of birth control - History of multiple drug allergies that may put the subject at greater risk during study participation in the opinion of the investigator", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Diabetic Neuropathy", "mesh_term": ["Diabetes Mellitus", "Peripheral Nervous System Diseases", "Neuralgia", "Diabetic Neuropathies"], "id": "NCT00073034"}